mRNA |
SL 0101-1 |
GDSC1000 |
pan-cancer |
AAC |
-0.1 |
0.005 |
mRNA |
ruxolitinib |
GDSC1000 |
pan-cancer |
AAC |
0.092 |
0.006 |
mRNA |
ruxolitinib |
CTRPv2 |
pan-cancer |
AAC |
0.095 |
0.007 |
mRNA |
RAF265 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.007 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.097 |
0.007 |
mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.097 |
0.01 |
mRNA |
navitoclax:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.093 |
0.01 |
mRNA |
navitoclax:birinapant (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.09 |
0.01 |
mRNA |
semagacestat |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.01 |
mRNA |
Bax channel blocker |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.02 |